IQVIA and CEPI Ally to Speed Drug Development for Future Disease Outbreaks

IQVIA and CEPI Ally to Speed Drug Development

In an effort to combat future disease outbreaks more quickly, IQVIA, a top biopharma data supplier and contract research organisation (CRO), and CEPI, a global non-profit that finances and organises the development of vaccines against future epidemics, have partnered. The “100 Days Mission,” a global effort to expedite clinical research for vaccines and other therapies aimed at emerging infectious illnesses, is the main emphasis of the collaboration.

Thank you for reading this post, don't forget to subscribe!

As per the agreement, CEPI will have access to IQVIA’s extensive global network of clinical trial sites as well as its proficiency in managing and analysing clinical research data. With the use of this data, CEPI will find and create novel vaccines and treatments for newly developing infectious diseases, expediting the clinical development process.

It is anticipated that the partnership would be crucial in assisting nations in being ready for pandemics and other infectious disease outbreaks in the future. IQVIA and CEPI intend to expedite the time it takes to introduce novel vaccines and therapies to the market by optimising the clinical research process.

Here are some particular instances of how CEPI and IQVIA are collaborating to expedite the development of new drugs:

IQVIA and CEPI Ally to Speed Drug Development

• CEPI is receiving assistance from IQVIA in order to map and identify the clinical research capacities of various nations and areas. With this data, regional consortia that may be swiftly assembled to carry out clinical trials in the case of an outbreak are being developed.
• In order to facilitate clinical research for newly emerging infectious diseases, IQVIA is also creating new instruments and technologies. For instance, IQVIA is creating a new platform for clinical trial data sharing that will facilitate data exchange between various clinical trial sites and researchers worldwide.
• Additionally, CEPI will have access to IQVIA’s knowledge of managing and overseeing clinical trial sites. In remote or resource-poor regions, CEPI will be able to guarantee that clinical trials are carried out to the highest standards thanks to this assistance.

The global effort to expedite medicine development and get ready for pandemics in the future has advanced significantly with the partnership between IQVIA and CEPI. Together, these two organisations are contributing to a safer world for all people.

What this means for the future:

IQVIA and CEPI Ally to Speed Drug Development

IQVIA and CEPI Ally to Speed Drug Development: The partnership between CEPI and IQVIA is a good step forward for world health in the future. These two organisations are contributing to the quicker and more effective release of new vaccines and medicines onto the market by optimising the clinical research process. To prevent pandemics and other infectious disease outbreaks in the future, this will be crucial.

Furthermore, the partnership is assisting in the development of clinical research capabilities in underprivileged areas of the globe. Even in the case of an outbreak, this will enable more rapid and effective clinical trial conduct in these areas. This is necessary to guarantee that everyone, wherever they may reside, gets access to the most recent, life-saving vaccinations and medical treatments.

IQVIA and CEPI Ally to Speed Drug Development: All things considered, the partnership between IQVIA and CEPI represents a major advancement in the worldwide endeavour to enhance everyone’s health and well-being.

read